Equities
Health CareMedical Equipment and Services
  • Price (GBX)991.60
  • Today's Change-51.67 / -4.95%
  • Shares traded5.60m
  • 1 Year change-12.48%
  • Beta0.8435
Data delayed at least 20 minutes, as of Mar 28 2024 17:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)4.39bn
  • Net income in GBP208.10m
  • Incorporated1937
  • Employees18.45k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SN.:LSE since
announced
Transaction
value
Cartiheal 2009 LtdDeal completed22 Nov 202322 Nov 2023Deal completed-2.97%330.00m
Data delayed at least 20 minutes, as of Mar 28 2024 17:06 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medacta Group SA437.45m40.56m2.11bn1.73k52.107.4623.344.832.322.3225.0016.200.79790.87085.92288,854.707.407.899.0910.5768.1070.439.2710.090.90044.800.381717.0116.8513.382.410.69378.32--
Elekta AB (publ)1.36bn106.84m2.22bn4.58k21.603.0111.761.633.743.7447.6026.820.62083.292.904,150,570.004.894.328.697.8937.9039.937.887.680.82194.020.410665.7915.957.83-18.28-6.9012.8611.38
Ambu A/S562.56m27.34m3.07bn4.70k125.975.5844.925.450.90140.901418.7120.360.70752.007.261,060,875.003.443.813.974.6256.9759.374.865.431.307.200.103822.897.4512.8880.65-13.006.67--
GN Store Nord A/S2.08bn26.19m3.17bn7.17k119.262.7713.811.521.531.53130.4365.840.59192.964.282,528,960.000.86884.911.577.4449.5553.291.476.820.48121.880.584736.84-3.0311.30-55.38-28.747.53--
Getinge AB2.37bn179.83m4.11bn11.12k24.491.9612.241.738.868.86116.85110.750.60272.745.78--4.605.316.096.9845.5447.837.648.690.77489.390.209935.3412.495.66-3.17---0.394434.49
Ypsomed Holding AG445.23m63.39m4.30bn2.20k67.778.5632.879.665.315.3137.3142.030.58884.925.75247,016.008.384.4412.706.7732.0426.9514.246.870.557730.610.261418.547.021.31121.92-0.303420.32-1.47
SCHOTT Pharma AG & Co KgaA775.78m135.44m5.26bn4.65k38.878.5429.686.791.051.056.014.78------194,928.30--------35.23--17.48--1.08--0.094--9.43--21.11------
ConvaTec Group PLC1.70bn103.10m5.93bn10.03k57.594.4221.713.500.05020.05020.82590.65480.58652.576.14--3.572.364.182.7356.0454.816.084.340.88352.630.4367141.923.373.18107.15-6.9312.3731.41
Amplifon SpA1.94bn132.89m6.60bn14.38k49.376.9818.273.410.68980.689810.024.880.621920.9910.38157,179.504.274.316.165.8123.5659.016.867.280.45196.310.579534.266.6510.66-12.219.0812.6815.68
Demant A/S2.58bn293.17m8.82bn21.62k29.998.17--3.4211.448.05100.5841.970.74312.055.881,037,923.008.468.2712.2013.2373.7274.1411.3811.340.95295.980.60750.0013.8910.0012.236.968.80--
Smith & Nephew plc4.39bn208.10m9.12bn18.45k43.782.2012.192.080.23840.23845.034.730.55620.75224.33237,952.602.644.103.294.9968.8271.394.748.020.724.840.371579.596.402.5017.94-16.884.24-8.12
Carl Zeiss Meditec AG1.79bn237.07m9.15bn4.82k38.53--130.815.103.103.1023.45--------434,177.70--9.56--11.7257.3557.8413.2813.15------34.479.8010.28-1.2018.0926.7914.87
Data as of Mar 28 2024. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

27.81%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202343.82m5.01%
Wellington Management Co. LLPas of 31 Dec 202042.67m4.88%
The Vanguard Group, Inc.as of 01 Mar 202433.60m3.84%
Norges Bank Investment Managementas of 01 Mar 202421.33m2.44%
BlackRock Fund Advisorsas of 01 Mar 202420.09m2.30%
Walter Scott & Partners Ltd.as of 01 Mar 202419.39m2.22%
T. Rowe Price Associates, Inc. (Investment Management)as of 01 Mar 202417.59m2.01%
Rathbones Investment Management Ltd.as of 01 Mar 202416.69m1.91%
Legal & General Investment Management Ltd.as of 01 Mar 202414.44m1.65%
Fidelity Management & Research Co. LLCas of 01 Mar 202413.54m1.55%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.